BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Biogen Inc. stands sixth on our list among the most ...

Biogen (($CC:HTER)) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has announced an update on its ...

In contrast, H.C. Wainwright reiterated a buy rating, highlighting the potential of felzartamab in establishing a nephrology franchise.

In contrast, H.C. Wainwright reiterated a buy rating, highlighting the potential of felzartamab in establishing a nephrology franchise. These developments reflect Biogen’s strategic focus on advancing ...

Biogen, one of the world's largest biotechnology companies, plans to invest $2 billion and build a new manufacturing facility ...

Additionally, Biogen has initiated a Phase 3 trial of felzartamab for primary membranous nephropathy (PMN), a rare kidney disease, with results expected in 2029. This marks the company’s third Phase 3 ...

Vera Therapeutics' Phase 3 data on atacicept sparks optimism for IgAN treatment, but competition and market challenges may ...